본문 바로가기

Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV in Asia: 24-Month findings from the observational BICSTaR study

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q2Scopus Q2
저널
MEDICINE105(5) · 2026
피인용
Web of Science 1Scopus 1
FWCI (Scopus)
0
JCR IF
JCR 2024 1.4
ISSN
0025-7974

저자

  1. Yang, Chia-Jui제1저자Far Eastern Mem Hosp, Dept Internal Med, New Taipei City, Taiwan
  2. Kim, Yeon-SookChungnam Natl Univ, Sch Med, Dept Internal Med, Div Infect Dis, Daejeon, South Korea
  3. Choi, Jun YongYonsei Univ, Coll Med, Dept Internal Med, Div Infect Dis, Seoul, South Korea
  4. Choy, Chiaw YeeNatl Ctr Infect Dis, Dept Infect Dis, Singapore, Singapore
  5. Lu, Po-LiangKaohsiung Med Univ, Coll Med, Sch Postbaccalaureate Med, Kaohsiung, Taiwan
  6. Tsai, Hung-ChinNatl Yang Ming Chiao Tung Univ, Sch Med, Taipei, Taiwan
  7. Ryu, JulieGlobal Med Affairs, Gilead Sci, Foster City, CA USA
  8. Harrison, RebeccaIQVIA, Real World Solut, London, England
  9. Chang, JackGilead Sci, Med Affairs, Taipei, Taiwan
  10. Mo, BillyGilead Sci, Med Affairs, Taipei, Taiwan
  11. 이선희Pusan Natl Univ, Sch Med, Dept Internal Med, Busan, South Korea
  12. Hung, Chien-Ching교신저자Natl Taiwan Univ Hosp, Yunlin Branch, Dept Internal Med, Yunlin, Taiwan

초록

BICtegravir Single Tablet Regimen is a multiregional, observational cohort study assessing the effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve (TN) and treatment-experienced (TE) people with HIV. We present 24-month data for the BICtegravir Single Tablet Regimen Asia cohort. Between December 2020 and March 2024, prospective and retrospective data were collected from TN and TE people with HIV receiving B/F/TAF in routine clinical care in the Republic of Korea, Singapore, and Taiwan. Endpoints at month 24 included effectiveness (HIV-1 RNA <50 copies/mL; missing = excluded and discontinuation = failure analyses), immunological endpoints (CD4 cell count and CD4/CD8 ratio), persistence, safety, and patient-reported outcomes (prospective cohort). Overall, 334 participants (252 prospective, 82 retrospective; 66 TN, 268 TE) were included in the analysis population. Most were male (97% TN, 93% TE) with ≥1 comorbidity (56% TN, 67% TE). At month 24, HIV-1 RNA was <50 copies/mL in 91% (50/55) of TN and 97% (225/331) of TE participants (missing = excluded analysis). Median (quartile [Q]1, Q3) CD4 count increased by +260 (155, 386; P < .001) cells/μL in TN and +40 (−65, 150; P = .008) cells/μL in TE participants. Median (Q1, Q3) CD4/CD8 ratio increased by +0.38 (0.21, 0.48; P < .001) in TN and +0.08 (0.00, 0.19; P < .001) in TE participants. Patient-reported outcomes indicated an improvement in mental health and a decrease in the number of bothersome symptoms in TN participants. Persistence at month 24 was high, with 98% (60/61) of TN and 97% (251/260) of TE participants remaining on B/F/TAF. Drug-related adverse events occurred in 9% (6/66) of TN and 8% (22/268) of TE participants, leading to B/F/TAF discontinuation in <1% (3/334) of participants, all of whom were TE. B/F/TAF demonstrated high levels of effectiveness, persistence, and tolerability over 24 months in people with HIV in Asia.

키워드

antiretroviral therapyAsiaB/F/TAFbictegravirreal-world evidence

식별자

Scopus EID
2-s2.0-105029338774
WoS UID
001680486200039